Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-823-5 | CAS number: 68916-18-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
ORAL
LD50: >2000 mg/kg bw (Coffea Canephora robusta)
LD50: 220 - 412 mg/kg bw (Caffeine)
INHALATION
LC50: 4.94 mg/l (Caffeine)
DERMAL
LD50: >2000 mg/kg bw (Caffeine)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Remarks:
- No further information provided.
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: roasted and ground beans of Coffea canephora robusta
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: refrigerated
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: not available
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The aqueous extract was obtained by infusion of roasted and ground beans of Coffea canephora robusta (Ccr). A filter coffee machine of Philips brand Daily collection insulated stainless timer HD7479/20, was used to prepare coffee. The infusion was made with 30 g of roast and ground beans of Ccr in 175 ml of distilled water. The filtrate obtained was evaporated in an oven at a temperature of 60 °C. The crystals obtained were pulverized. The captured fine powder was kept refrigerated in sterile glass jars sealed. This technique yielded 3g of dry extract.
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel:
- Final preparation of a solid: not applicable
OTHER SPECIFICS:
To extract caffeine, one gram of freeze-dried coffee ground powder was transferred to a volumetric flask of 50 ml. An amount of 35 ml of methanol was added and the resulting suspension was immersed in an ultrasonic bath for 10 minutes. The suspension was subsequently cooled to room temperature and filtered on Whatman paper N°4.
The HPLC system consisting of a pump, a UV detector, and controlled by a computer (software) was used for assaying the proportion of caffeine in the extract. Qualitative analysis of caffeine was obtained by comparison of retentions times of the compounds eluted to the retention times of the reference solutions. The concentrations were determined from the average of the peak areas of the reference solutions. Caffeine content being the average of 3 tests, the concentration of caffeine in the extract is given by the following formula:
SC = S area x CW/ W area, where
SC = sample concentration
CW = Concentration witness
W area = peak area witness
S area = peak area sample - Species:
- rat
- Strain:
- Wistar
- Remarks:
- albino
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Pasteur Institute Adipodoumé, Abidjan, Ivory Coast
- Females (if applicable) nulliparous and non-pregnant: not specified
- Age at study initiation: 8-10 weeks
- Weight at study initiation: between 100 and 120 g
- Fasting period before study: not specified
- Housing: wire cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 ± 3ºC
- Humidity (%): 50%
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): 12/12 hours - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Test solutions and control solution were administered by a stomach tube.
- Doses:
- 2000 and 5000 mg/kg bw
- No. of animals per sex per dose:
- 3 female rats
- Control animals:
- yes
- Remarks:
- control animals received distiled water
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Clinical signs were observed at 30 minutes, 1, 4, 8 , 24 and 48 hours.
The weight of each animal was determined before administration and then every third day.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other:
Organs such as the kidney, liver and heart were removed and weighed.
The biochemical parameters such urea, blood sugar, creatinine, transaminases ASAT and ALAT and hematological parameters such as leukocytes, erythrocytes and platelets counts, hemoglobin, hematocrit, MCV, MCHC were determined. - Statistics:
- The statistical analysis was performed using the Graph Pad Prism 5 software. The analysis of variance ANOVA (One-way ANOVA) followed by the Tukey-Kramer test was used for comparison of results. The difference is considered statistically significant when P <0.05.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 - < 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two deaths occured at the dose of 5000 mg/kg bw after 24 and 48 hours. No deaths related to the extract administration were recorded at the dose of 2000 mg/kg bw.
- Clinical signs:
- other: During the first hour after administration of the extract, the rats from experimental batches seemed agitated. This excitation was attributed to caffeine, which increases, neuromuscular transmission and increases the neural excitability reducing the disch
- Gross pathology:
- No effects were observed on liver, heart and kidney in experimental and control animals.
- Other findings:
- Caffeine content in the aqueous extract of roasted and ground beans of Coffea Canephora robusta was determined at 7.5%.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In an acute oral toxicity study in rats, conducted according to OECD test guideline 423, a LD50 value was determined between 2000 and 5000 mg/kg body weight for aqueous extract of roasted and ground beans of Coffea canephora robusta containing 7.5% of caffeine.
- Executive summary:
The acute oral toxicity study in rats, conducted according to OECD test guideline 423 was performed to assess the acute toxicity potential of aqueous extract of roasted and ground beans of Coffea canephora robusta.
Two sets of 3 animals received Coffea canephora robusta extract at 2000 mg/kg body weight, another set of 3 animals received a dose of 5000 mg/kg body weight and a control group were administered distilled water, by stomach tube.
Clinical signs including diarrhea, lethargy, excitability and death were observed at 30 minutes, 1, 4, 8, 24 and 48 hours. The relative weights of organs (kidneys, liver and heart) were recorded at the beginning of the study, and then every third day. At the end of the study, animals were sacrificed and gross pathology was performed. Additionally, the biochemical and hematological parameters were determined.
No deaths were observed at 2000 mg/kg body weight, two deaths occurred at the dose of 5000 mg/kg body weight after 24 and 48 hours. There were no significant effects on the body weight in animals receiving coffee extract in comparison to control animals. Additionally, all animals from control and treatment groups gained weight during the experiment.
The administration of aqueous extract of roasted and ground beans of Coffea Canephora robusta did not have any significant effect on the relative weights of organs and biochemical and hematological parameters
The value of the lethal dose 50 (LD50) in this study has been determined between 2000 and 5000 mg/kg body weight, indicating that the aqueous extract of roasted and ground beans of Coffea Canephora robusta containing 7.5% of caffeine has relatively low acute toxicity and does not meet GHS criteria for acute toxicity classification.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- NCTR Standard Procedure, similar to OECD guideline 401
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine, purity was 99.9% (analyzed)
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: soluble in water
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: a stock solution of caffeine/sodium benzoate was prepared on April 6 and 7, 1981. Sodium benzoate was added to enhace the solubility of caffeine. Caffeine stock solutionn contained 160 mg/ml caffeine and 160 mg/ml sodium benzoate. Serial dilutions were made with a sodium benzoate water solution so that final concentrations of the sodium benzoate reminded contstant and caffeine concentrations decreased by one-half.
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- other: sodium benzoate water solution
- Details on oral exposure:
- Caffeine was administered one time by oral exposure (gavage) in an aqueous sodium benzoate solution. Sodium benzoate increased the solubility of caffeine.
- Doses:
- 50, 100, 200, 400, and 800 mg/kg bw
- No. of animals per sex per dose:
- 6
- Control animals:
- no
- Details on study design:
- Caffeine, dissolved in an aqueous solution containing 160 mg/ml sodium benzoate, was administered by oral intubation in an approximate volume of 0.5 ml per 100 g body weight. The five dosage groups ( each with six male and six female rats) were administered caffeine at a dose of either 800, 400, 200, 100 or 50 mg/kg body weight. A single oral dose was given in the morning after a period of 18 hours of fasting. Animals were observed, clinical signs recorded and dead animals removed in the morning and afternoon of each day following administration of the compound for a period of 14 days. Rats were removed from cages and individually observed during the morning and afternoon observation periods (approximately 9-10 a.m. and 2-3 p.pm.). All animals were subjected to a routine necropsy. Gross observations were recorded and tissues with apparent lesions were preserved and subjected to routine histological evaluation.
- Statistics:
- The SAS probit procedure was used to estimate LD50 and LD10 values, as well as the upper and lower 95% confidence limits on these two values. Male and female rats were combined in making these estimates. Estimates of LD10 values were determined from the plots of the results.
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- ca. 220 mg/kg bw
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 240 mg/kg bw
- Mortality:
- All deaths occured within the first three days of the experiment and in the two highest dosage groups.
- Clinical signs:
- other: Clinical symptoms occured on the days 1-3 after gavaging and frequently disappeared by the end of the 14 day observation period. They included: discharge from the mouth, letargy, labored or slow respiration, discolored skin, walk-toe, sunken eyes.
- Gross pathology:
- Hemorrage and autolysis of the thymus in one of the female rat. It was concidered coincidental and not dose-related.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- In an acute oral toxicity study in Fischer 344 male and female rats, conducted according to a conventional method, a LD50 value for caffeine was determined at approximately 220 and 240 mg/kg body weight for male and female rats respectively.
- Executive summary:
The acute oral toxicity study in Fisher 344 male and female rats conducted according to conventional method was performed to assess the acute toxicity potential of caffeine.
Groups of 6 rats per sex were administered the test substance by gavage at dose levels of 50, 100, 200, 400, and 800 mg/kg body weight. The LD50 was determined to be between 200 and 400 mg/kg body weight for male and female rats. However, the slope of the the LD50 curve was rather steep, especially for males, therefore, the value of LD50 determined from the plotted data were approximetely 220 and 240 mg/kg body weight for male and female rats respectively, allocating caffeine in Category 3 based on GHS criteria for acute toxicity classification.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine, purity of 98.5 - 100 % w/w
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: soluble in water
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not available
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5%
- Details on oral exposure:
- Rats were given a single dose of the test substance
- Doses:
- 178, 261, and 383 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- Animals were observed for 14 days
- Key result
- Dose descriptor:
- LD50
- Effect level:
- >= 261 - <= 383 mg/kg bw
- Mortality:
- Three males and all females of the high dose group died within the first day after dosing.
- Gross pathology:
- Pathology revealed general congestive hyperemia in the animals that died; and no abnormalities were found in the survivors.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- In an acute oral toxicity study in Wistar male and female rats, conducted according to a conventional method, a LD50 value was between 261 and 383 mg/kg body weight for caffeine.
- Executive summary:
The acute oral toxicity study in male and female rats conducted according to conventional method was performed to assess the acute toxicity potential of caffeine.
Groups of 5 male and 5 female Wistar rats were given a single dose of the test substance at dose levels of 178, 261, and 383 (by gavage; dissolved in 0.5% aqueous carboxymethyl cellulose) and were observed for 14 days.
Three males and all females of the high dose group died within the first day after dosing. Pathology revealed general congestive hyperemia in the animals that died; and no abnormalities were found in the survivers.
The value of the lethal dose 50 (LD50) in this study has been determined between 261 and 383 mg/kg body weight, allocating caffeine in Category 3/4 based on GHS criteria for acute toxicity classification.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- GLP compliance:
- no
- Test type:
- standard acute method
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: not available
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not available
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
- Final preparation of a solid: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Route of administration:
- oral: gavage
- Details on oral exposure:
- Animals were deprived of food for 18-20 hours prior to dosing by oral gavage. After dosing, the animals were permitted access to food ad libitum.
- Doses:
- Animals were dosed in groups of 10, usually with a geometric progression of 1.4 between successive dose groups.
- Details on study design:
- Aminals were observed for a total of 2 weeks after dosing.
- Statistics:
- Data were analyzed by the PROBIT procedure of the SAS system.
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 344 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- In an acute oral toxicity study in Sprague-Dawley male rats, conducted according to a conventional method, a LD50 value was at 344 mg/kg body weight for caffeine.
- Executive summary:
The acute oral toxicity study in Sprague-Dawley male rats conducted according to conventional method was performed to assess the acute toxicity potential of caffeine.
Animals were dosed in groups of 10, with a geometric progression of 1.4 between successive dose groups, and were observed for a total of 2 weeks after dosing.
The value of the lethal dose 50 (LD50) in this study has been determined at 344 mg/kg body weight, allocating caffeine in Category 4 based on GHS criteria for acute toxicity classification.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- GLP compliance:
- no
- Test type:
- up-and-down procedure
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: not available
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not available
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
- Final preparation of a solid: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Route of administration:
- oral: gavage
- Details on oral exposure:
- Animals were deprived of food for 18-20 hours prior to dosing by oral gavage. After dosing, the animals were permitted access to food ad libitum.
- Doses:
- The dose for each animal was based on fasted body weight. Animals were dosed singly, at least I day apart. If an animal died or appeared moribund the day after dosing, the dose for the next animal was decreased by a factor of 1/1.3; otherwise the dose for the next animal was increased by a factor of 1.3
- Details on study design:
- Animals were observed 1 week after dosing
- Statistics:
- Studies were analyzed by the method of maximum likelihood using the SAS procedure NLIN.
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 421 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- In an acute oral toxicity study in Sprague-Dawley male rats, conducted according to an up-and down method, a LD50 value was at 412 mg/kg body weight for caffeine.
- Executive summary:
The acute oral toxicity study in Sprague-Dawley male rats conducted according to an up-and down method was performed to assess the acute toxicity potential of caffeine.
Animals were dosed singly, at least 1 day apart. If an animal died or appeared moribund the day after dosing, the dose for the next animal was decreased by a factor of 1/1.3; otherwise, the dose for the next animal was increased by a factor of 1.3. Animals were observed for 1 week after dosing.
The value of the lethal dose 50 (LD50) in this study has been determined at 412 mg/kg body weight, allocating caffeine in Category 4 based on GHS criteria for acute toxicity classification.
Referenceopen allclose all
Effects on the organs weigh in animals receiving 2000 mg/kg of bw of the extract.
Organ (g) |
Control rats |
Experimental rats |
Liver |
4.08±0.41 |
4.17±0.28 |
Heart |
0.43±0.26 |
0.47±0.14 |
Kidney |
0.64±0.025 |
0.67±0.02 |
Effects on biochemical parameters in animals receiving 2000 mg/kg of bw of the extract.
Parameter |
Control rats |
Experimental rats |
Urea (g/L) |
0.19±0.01 |
0.18±0.02 |
Blood sugar (g/L) |
0.95±0.16 |
1.05±0.20 |
Creatinine (mg/L) |
8.67±0.95 |
7.67±1.04 |
Transaminase ASAT (U/L) |
35.33±3.06 |
32.0±4.57 |
Transaminase ALAT (U/L) |
39.33±1.67 |
37.67±2.62 |
Effects on leukocytes parameters in animals receiving 2000 mg/kg of bw of the extract.
Parameter |
Control rats |
Experimental rats |
Polymorphonuclear neutrophils (%) |
14.0±2.65 |
12.67±1.15 |
Polymorphonuclear eosinophils (%) |
1.67±0.58 |
1.33±0.58 |
Polymorphonuclear basophils (%) |
0.0±0.00 |
0.0±0.00 |
Lymphocytes (%) |
79.33±3.08 |
81.0±2.00 |
Monocytes (%) |
5.0±1.00 |
5.0±1.00 |
Effects on hematological parameters in animals receiving 2000 mg/kg of bw of the extract.
Parameter |
Control rats |
Experimental rats |
Leukocytes (109/L) |
8.43±2.21 |
10.53±1.77 |
Erythrocytes (1012/L) |
6.93±0.63 |
7.17±0.24 |
Hemoglobin (g/dL) |
13.07±0.57 |
13.73±0.40 |
Hematocrit (%) |
37.1±1.81 |
39.47±1.40 |
MCV (fl) |
51.60±1.15 |
54.37±1.30 |
MCH (pg) |
17.87±0.75 |
18.57±1.07 |
MCHC (g/dL) |
34.40±1.02 |
34.67±0.85 |
Platelets (109/L) |
728±109 |
753±127 |
Administration of roasted and ground beans of Coffea canephora robusta extract did not have any effect on biochemical and hematological parameters. Normal values of urea and creatinine suggest that this extract did not alter the structure and renal functions. In addition, the levels of transaminases (ALAT) and (ASAT) were not altered during the experiment indicating that liver and to a lesser degree, muscles were not affected.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- 2 concentrations only
- Principles of method if other than guideline:
- A third test group (as required by the OECD guideline no. 403) was not included since a third dose level (higher than 4.94 mg/l) was expected to be lethal to all exposed animals.
- GLP compliance:
- no
- Test type:
- traditional method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine, purity of 99.5 - 100% (dried substance)
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: soluble in water
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not available
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose/head only
- Vehicle:
- other: Aerosil R 972 at 2%
- Details on inhalation exposure:
- The rats were exposed for 4 hours and observed for 14 days (day of exposure = day 0).
- Concentrations:
- Nominal concentrations of 2.48 and 4.94 mg/l
- No. of animals per sex per dose:
- 5
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- ca. 4.94 mg/L air (nominal)
- Mortality:
- No deaths were observed at the low dose level.
In the high dose group, 6/10 animals died. Late deaths were observed; one male each died at day 0 and 7, respectively; 2, 1, and 1 female died at day 0, 1, and 2, respectively. - Clinical signs:
- other: Clinical signs of toxicity included changes in respiration (irregular, accelerated, intermittent, gasping), eyelid closure, salivation, restlessness, attempts to escape, reddish nasal discharge, apathy, and (in the high dose group only) decreased pain ref
- Gross pathology:
- Pathology revealed general congestion, bloody ulcers in the glandular stomachs, and/or intensified hyperemia in the animals that died. No pathological changes were observed in the survivors.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- In an acute inhalation toxicity study in Wistar male and female rats conducted according to OECD test guideline 403, the LC50 value was determined at 4.94 mg/l for caffeine aerosol.
- Executive summary:
The acute inhalation toxicity study in Wistar male and female rats conducted according OECD test guideline 403 was performed to assess the acute toxicity potential of caffeine aerosol.
Groups of 5 Wistar rats per sex were exposed to caffeine aerosol at nominal concentrations of 2.48 and 4.94 mg/l using a head-nose inhalation system. The rats were exposed for 4 hours and observed for 14 days. No deaths were observed at the low dose level. In the high dose group, 6/10 animals died. Late deaths were observed; one male each died at day 0 and 7, respectively; 2, 1, and 1 female died at day 0, 1, and 2, respectively.
Clinical signs of toxicity included changes in respiration (irregular, accelerated, intermittent, gasping), eyelid closure, salivation, restlessness, attempts to escape, reddish nasal discharge, apathy, and (in the high dose group only) decreased pain reflex and death. Pathology revealed general congestion, bloody ulcers in the glandular stomachs, and/or intensified hyperemia in the animals that died. No pathological changes were observed in the survivors.
The value of the lethal concentration 50 (LC50) in this study has been determined at 4.94 mg/l, allocaing caffeine in Category 4 based on GHS criteria for acute toxicity classification.
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline available
- GLP compliance:
- no
- Test type:
- other: behavioral and neurochemical pharmacology study
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine, purity of 99.5 - 100% (dried substance)
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: not available
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: caffeine was volatilized in the volatilization device.
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
- Final preparation of a solid: not available
OTHER SPECIFICS: The volatilization device consisted of a stainlesssteel tube (length 10 cm, i.d. 0.6 mm) filled with steel wool used in order to keep the caffeine at the top of the tube. The tube was closely connected to a plastic syringe (60 ml) through which a vacuum system was set up (representing the human’s respiratory system). At the end of the tube, a lighter was turn on and caffeine was heated until the vapor generation started. - Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: IIBCE animal facilities, Montevideo
- Females (if applicable) nulliparous and non-pregnant: only male used
- Age at study initiation: not available
- Weight at study initiation: 250–310 g
- Fasting period before study: not specified
- Housing: five animals in plastic cages (50 x 37.5 x 21 cm3)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: not specified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2ºC,
- Humidity (%): not specified
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): 12 h day–night cycle, lights on at 7h00 am
IN-LIFE DATES: From: To: not available - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- The caffeine vapor collected in the plastic syringe was injected through a valve placed in one of the walls of a whole-body chamber (inhalation chamber; 23 x 15 x 10 cm3) where animals were separately placed and exposed acutely to different doses of volatilized caffeine for 10 min.
- Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- GC–MS
- Duration of exposure:
- 10 min
- Concentrations:
- 10, 25, and 50 mg
- Control animals:
- yes
- Details on study design:
- After the exposure to the volatilized drug—or control—animals were removed from the inhalation chamber and placed in an Open Field paradigm (OF, a square box of 60 9 60 cm2 with red 40-cm-high acrylic sides) associated to the EthoVision XT 7 software (Noldus, The Netherlands). Using this video tracking software, the horizontal locomotor activity defined as the total distance moved in meters (m) and velocity of movement were measured.
Locomotor and exploratory (number of rearings) activities were registered during 30 and 15 min, respectively. During all the experiments the inhalation chamber and the OF were cleaned with alcohol 30 % before placing the following rat. All experiments were done between 9 a.m. and 3 p.m. In order to measure plasmatic caffeine levels, plasma samples of each animal (control and treated) were collected immediately after the end of behavioral recordings.
Animals were killed by decapitation and trunk blood was collected in plastic Falcon tubes containing a solution of citric acid (0.05 mM), sodium citrate (0.09 mM), and sodium fluoride (0.2 mM). Blood was then centrifuged (Centrifuge, Thermo Scientific) for 15 min at 3000 g and 4ºC. The recovered plasma was stored at -80ºC until assay. - Statistics:
- Data are given as mean ± standard error of the mean (SEM) and were analyzed by two-way (time and pretreatment) analysis of variance (ANOVA) for repeated measures followed by post hoc Newman- Keuls multiple comparison test and by one-way ANOVA for independent measures (treatment) followed by Newman–Keuls test. Linear regression was applied. Statistical significance was set at P<0.05.
- Sex:
- male
- Dose descriptor:
- other: LC50
- Effect level:
- > 50 other: mg
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- No mortality was observed
- Clinical signs:
- other: Not observed
- Body weight:
- Not determined
- Gross pathology:
- Not determined
- Other findings:
- Stimulant effect of volatilized caffeine was observed. Distance moved of rats treated with 50 mg of caffeine was significantly higher than control group (P<0.001), caffeine 25 mg (P<0.01), and 10 mg (P<0.01). The effect of lower doses of caffeine (10 and 25 mg) was not significantly different compared to the control group. Distance moved profile was similarly accompanied by the changes in the velocity of movement and rearing behavior. Animals stimulated with caffeine 50 mg were faster than control group (P>0.001), caffeine 25 mg (P<0.01), and caffeine 10 mg (P<0.01). Again, the effects of lower doses of caffeine (10 and 25 mg) were not significantly different from control animals. Caffeine at 50 mg (P<0.05) but not at 10 or 25 mg doses significantly increased the number of rearings.
Additionally, blood analysis showed a dose-dependent stimulant effect and a significant increment in extracellular dopamine levels after the acute treatment of caffeine. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- No deaths or undesirable effects of caffeine were noted in Wistar male rats exposed to maximum of 50 mg volatilized caffeine during one inhalation session.
- Executive summary:
To study the behavioral and neurochemical pharmacology of caffeine, Wistar male rats were exposed to 10, 20 and 50 mg of volatilized caffeine during one inhalation session of 10 min in the whole-body chambers.
The stimulant effect of caffeine was automatically recorded for several hours and plasmatic levels of caffeine were measured. No deaths or undesirable effects of caffeine were noted. A dose-dependent stimulant effect such as distance moved, velocity of movement and rearing behavior, induced by volatilized caffeine was observed and this effect was directly related with caffeine plasmatic levels. A significant increase in the extracellular dopamine was achieved after 50 mg of volatilized caffeine exposure.
The results of this study support the conclusion from the acute inhalation study that pure caffeine is considered of low toxicity to rats by inhalation route.
Referenceopen allclose all
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- not specified
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: caffeine (anhydrous powder), purity of 98.5 - 100 % w/w
- Expiration date of the lot/batch: not available
- Purity test date: not available
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not available
- Stability under test conditions: not available
- Solubility and stability of the test substance in the solvent/vehicle: not available
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not available
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not available
- Preliminary purification step (if any): not available
- Final dilution of a dissolved solid, stock liquid or gel: not available
- Final preparation of a solid: not available
OTHER SPECIFICS: none - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- A 24-hour semiocclusive application of a 50% (w/v) aqueous suspension of the test substance. After 24 hours, the patches were removed, and the application sites were washed with water.
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- Observation period of 14 days post exposure.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No deaths were recorded.
- Clinical signs:
- other: No signs of toxicity were observed within the 14-day observation period.
- Gross pathology:
- No local/pathological findings were observed within the 14-day observation period.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LD50 value in this study has been determined at >2000 mg/kg body weight, indicating that the aqueous caffeine solution has low acute toxicity and it does not meet the classification criteria for skin irritation under the CLP Regulation (EC) No 1272/2008
- Executive summary:
The acute dermal toxicity study in male and female Wistar rats was performed to assess the acute toxicity potential of caffeine solution.
A 24-hour semiocclusive application of a 50% (w/v) aqueous suspension of caffeine at 2000 mg/kg body weight was applied on five male and five female Wistar rats. After 24 hours, the patches were removed, and the application sites were washed with water. No deaths, signs of toxicity, or local/pathological findings were observed within the 14-day observation period.
The LD50 value in this study has been determined at >2000 mg/kg body weight, indicating that the aqueous caffeine solution has relatively low acute toxicity and does not meet GHS criteria for acute toxicity classification.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
ORAL
The acute oral toxicity study in rats, conducted according to OECD test guideline 423 was performed to assess the acute toxicity potential of aqueous extract of roasted and ground beans of Coffea canephora robusta.
Two sets of 3 animals received Coffea canephora robusta extract at 2000 mg/kg body weight, another set of 3 animals received a dose of 5000 mg/kg body weight and a control group were administered distilled water, by stomach tube.
Clinical signs including diarrhea, lethargy, excitability and death were observed at 30 minutes, 1, 4, 8, 24 and 48 hours. The relative weights of organs (kidneys, liver and heart) were recorded at the beginning of the study, and then every third day. At the end of the study, animals were sacrificed and gross pathology was performed. Additionally, the biochemical and hematological parameters were determined.
No deaths were observed at 2000 mg/kg body weight, two deaths occurred at the dose of 5000 mg/kg body weight after 24 and 48 hours. There were no significant effects on the body weight in animals receiving coffee extract in comparison to control animals. Additionally, all animals from control and treatment groups gained weight during the experiment.
The administration of aqueous extract of roasted and ground beans of Coffea Canephora robusta did not have any significant effect on the relative weights of organs and biochemical and hematological parameters
The value of the lethal dose 50 (LD50) in this study has been determined between 2000 and 5000 mg/kg body weight, indicating that the aqueous extract of roasted and ground beans of Coffea Canephora robusta containing 7.5% of caffeine has relatively low acute toxicity and does not meet the criteria set in the CLP Regulation (EC) 1272/2008 for acute toxicity classification.
The physiological effects of coffee are generally attributed to caffeine. Caffeine is a stimulant of the central nervous system, respiration, and skeletal muscles; other activities include cardiac stimulation, coronary dilation, smooth muscle relaxation, and diuresis. Generally, Arabica coffee extracts contain less caffeine.
Several acute oral rat studies for caffeine were published, in which caffeine showed moderate toxicity after oral uptake showing clinical symptoms of toxicity such as dyspnoea and staggering. LD50 values were ranging from 220 to 412 mg/kg body weight.
INHALATION
The acute inhalation toxicity study in Wistar male and female rats conducted according OECD test guideline 403 was performed to assess the acute toxicity potential of caffeine aerosol.
Groups of 5 Wistar rats per sex were exposed to caffeine aerosol at nominal concentrations of 2.48 and 4.94 mg/l using a head-nose inhalation system. The rats were exposed for 4 hours and observed for 14 days. No deaths were observed at the low dose level. In the high dose group, 6/10 animals died. Late deaths were observed; one male each died at day 0 and 7, respectively; 2, 1, and 1 female died at day 0, 1, and 2, respectively.
Clinical signs of toxicity included changes in respiration (irregular, accelerated, intermittent, gasping), eyelid closure, salivation, restlessness, attempts to escape, reddish nasal discharge, apathy, and (in the high dose group only) decreased pain reflex and death. Pathology revealed general congestion, bloody ulcers in the glandular stomachs, and/or intensified hyperemia in the animals that died. No pathological changes were observed in the survivors.
The value of the lethal concentration 50 (LC50) in this study has been determined at 4.94 mg/l, allocating caffeine in Category 4 based on criteria set in the CLP Regulation (EC) 1272/2008 for acute toxicity classification.
To study the behavioral and neurochemical pharmacology of caffeine, Wistar male rats were exposed to 10, 20 and 50 mg of volatilized caffeine during one inhalation session of 10 min in the whole-body chambers.
The stimulant effect of caffeine was automatically recorded for several hours and plasmatic levels of caffeine were measured. No deaths or undesirable effects of caffeine were noted. A dose-dependent stimulant effect such as distance moved, velocity of movement and rearing behavior, induced by volatilized caffeine was observed and this effect was directly related with caffeine plasmatic levels. A significant increase in the extracellular dopamine was achieved after 50 mg of volatilized caffeine exposure.
DERMAL
The acute dermal toxicity study in Wistar male and female rats was performed to assess the acute toxicity potential of caffeine solution. A 24-hour semiocclusive application of a 50% (w/v) aqueous suspension of caffeine at 2000 mg/kg body weight was applied on five male and five female Wistar rats. After 24 hours, the patches were removed, and the application sites were washed with water. No deaths, signs of toxicity, or local/pathological findings were observed within the 14-day observation period.
The value of the lethal dose 50 (LD50) in this study has been determined at >2000 mg/kg body weight, indicating that the aqueous caffeine solution has relatively low acute toxicity and does not meet
criteria set in the CLP Regulation (EC) 1272/2008 for acute toxicity classification.
Justification for classification or non-classification
Coffee and its natural preparations are generally recognized as safe for human consumption. Coffee extracts have a wide spectrum of actions and therefore, they are also used in many types of cosmetics. The physiological effects of coffee are generally attributed to caffeine. Due to caffeine’s direct absorption to the blood stream, bypassing the hepatic first-pass effect, its alveolar absorption is not considered to differ from the oral and/or intravenous route, indicating that the physiological effects of caffeine will not vary depending on different routes of exposure.
Based on the low acute oral toxicity of Coffea Canephora robusta aqueous extract (LD50 >2000 mg/kg body weight) and low to moderate acute oral, inhalation and dermal toxicity of caffeine, a minor constituent of Coffee, bean, roasted, ext. no acute oral, inhalation and dermal toxicity is expected for Coffee, bean, roasted, ext. and therefore, no classification for acute toxicity is warranted according to the criteria set in the CLP Regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.